Abstract: The invention relates to a method for predicting mycobacterial drug resistance by isolating mycobacterial nucleic acid from a sample, obtaining a sample sequence from the nucleic acid, aligning and comparing the sample sequence to a reference sequence and determining for each reference position whether the sample sequence value is the same as a particular sequence value assigned to the position in a table. If both values are the same, a position weight value is assigned to the position. A predictor value is obtained by adding all position weight values and the predictor value is compared to a threshold value. If the predictor value is smaller than the threshold value, drug resistance is predicted. The invention encompasses a system for practicing the method, and the use of certain antibacterial drugs to treat infections by pathogens, resistance of which has been determined by the method of the invention.

Abstract: The invention relates to a method for labeling a target compound with a radiometal by photochemically induced conjugation. Furthermore, a chelating compound for use in said method is provided. The chelating compound is characterized by an arylazide moiety which can be photo-conjugated to a target compound and a chelator moiety which can be radiolabelled. The photo-conjugation and radiolabelling are both performed at basic pH performed in a simultaneous one-pot reaction.

Abstract: The invention relates to computation of optical flow using event-based vision sensors.

Abstract: The present invention relates to novel compositions comprising specific consortia of living bacteria strains; to the manufacturing of such compositions, particularly by co-cultivation; and to the use of such compositions in pharmaceutical applications, such as the treatment of diseases associated with intestinal microbiota dysbiosis, particularly intestinal infections such as CDI (Clostridium difficile infection) and IBD (Inflammatory bowel diseases). When compared to the traditional FMT therapy () the inventive compositions () are more efficient and safer as demonstrated on an acute colitis model and therefore more appropriate for therapeutic use.

Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of a condition or disorder selected from a pruritic condition or an allergic condition, of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating pruritus, preferably pruritus associated with a pruritic condition or an allergic condition such as allergic dermatitis, of equine mammals, preferably of horses.

Abstract: Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ligand is coordinated to the transition metal and the radioisotope to link the transition metal and the radioisotope and pendent ligands are coordinated to each of the transition metal and the radioisotope to stabilise the complex. The multinuclear complexes may include a radioisotope or radioelement that can be detected by medical equipment and may find use in therapy and/or the diagnosis of disease in patients.

Abstract: The invention relates to a tetrameric polypeptide comprising a first polypeptide chain comprising a first VL antigen binding domain and a first CL constant domain, a second polypeptide chain comprising a first VH antigen binding domain, a first CH1 constant domain, a first CH2 constant domain and a first CH3 constant domain, a first ligand binding to a HER2 D4 epitope linked to the N-terminus of said first VL antigen binding domain or said first VH antigen binding domain by a first interdomain amino acid linker, a third polypeptide chain comprising a second VL antigen binding domain and a second CL constant domain, a fourth polypeptide chain comprising a second VH antigen binding domain, a second CH1 constant domain, a second CH2 constant domain and a second CH3 constant domain and a third ligand binding to a HER2 D4 epitope linked to the N-terminus of said second VL antigen binding domain or said second VH antigen binding domain by a second interdomain amino acid linker, wherein the VL antigen binding domain

Abstract: The present invention is directed to polypeptides and compositions thereof useful for the prevention or treatment of an inflammatory bowel disease in particular Crohn's disease or ulcerative colitis (UC), and of coeliac disease. More particularly, the invention relates to agents and compositions thereof that useful for the prevention and treatment of hypersensitivity and/or hyperirritability of the colon and/or small intestine.

Abstract: The present invention relates to a cell culture device (1) for use with an optical microscope (40), comprising a housing (10) that is configured to be placed onto a stage of an optical microscope (40) in front of an objective (41) of the microscope (40), the housing (10) enclosing an internal space (11) of the housing (10), a removable flow chamber (2) enclosing an internal space (20) for accommodating a cell culture (CC) comprising living biological cells, a heater (3) arranged in the internal space (11) of the housing (10) for heating said fluid medium (M) to be guided through the flow chamber (2), a first flow path (P1) arranged in the internal space (11) of the housing (10) for guiding said fluid medium (M) towards the flow chamber (2) via said heater (3), and a second flow path (P2) arranged in the internal space (11) of the housing (2) for guiding said fluid medium (M) away from the flow chamber (2), and a pump (4) for pumping said fluid medium (M) through the first flow path (P1) into the internal spac

Abstract: The invention relates to a method for selecting a sequence set from a library of expressed nucleic acid sequences, wherein cells are provided, each cell comprises an expressed nucleic acid sequence expressed as a target protein. The cells are encapsulated by treating them with a cationic polysaccharide and subsequently treating them with an anionic polysaccharide, yielding encapsulated cells, perforating the membrane of the encapsulated cells, yielding solubilized compartments, contacting them with a ligand to said target protein, the ligand bearing a detectable label, and selecting a subset of solubilized compartments as a function of detectable label and isolating the expressed nucleic acid sequences from the selection as a selected sequence set.

Abstract: The invention relates to a radial blood pump (1) for supporting a blood flow (106) in a human or animal heart (205) comprising a first and a second inlet channel (41, 42), a first outlet channel (51, 52), a first electric motor (71) comprising a first stator (77) and a first internal rotor (75), wherein the first electric motor (71) is configured to drive an impeller (2, 2a, 2b) arranged at an intersection of the first with the second inlet channel (41, 42), wherein the impeller (2, 2a, 2b) is connected to the first internal rotor (75) and wherein the impeller (2, 2a, 2b) comprises a merging portion (22) arranged at the intersection, where a merging of a first blood flow (106) coming from the first inlet channel (41) and a second blood flow (107) coming from the second inlet channel (42) takes place, wherein the impeller (2, 2a, 2b) is configured to pump the first and second blood flow (106, 107) from the first and second inlet channel (41, 42) via the merging portion (22) to the first outlet channel (51), a

Abstract: A method for monitoring and visualizing a patient's medical condition, wherein a graphical representation of the patient comprising a body having at least a torso and a head, as well as particularly two legs and two arms, is displayed using a display device, wherein said displayed graphical representation comprises at least one region which is allocated to at least one or several provided (e.g. measured and/or determined) patient monitoring quantities, and wherein the appearance of the at least one region is altered in real-time when the at least one patient monitoring quantity to which said at least one region is allocated changes.

Abstract: The present invention concerns a method of generating a population of skeletal muscle derived human muscle precursor cells. For this purpose, a specialized FBS-free cell growth medium is used. The invention further concerns a composition comprising such a population of hMPCs for use as a medicament, especially in the treatment of skeletal muscle dysfunction.

Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.

Abstract: The invention relates to a human lnterieuldn-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hlL-2 inhibits binding of hlL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.

Abstract: A spectrophotometric apparatus for determining optical parameters in a scattering medium based on the measurement of attenuation of light propagating through said medium by diffusion. To eliminate the detrimental effect of light being guided in an intermediate optical layer between a surface of the medium and a contact surface of the apparatus, either a multitude of optical barriers may be formed in the contact surface or the angular range over which light is emitted or received by the apparatus may be limited by appropriate means. With both of these alternative approaches, light propagation in the intermediate layer can be suppressed, leading to increased measurement accuracy. This is particularly beneficial for building an oximeter with improved precision. Further aspects include features for improving the applicability of the apparatus on curved surfaces such as the strongly curved skulls of neonates.

Abstract: The invention relates to a method for processing large multiplexed image data of a biological sample, the method comprising the steps of, recording a plurality of images of a biological sample, wherein the plurality of images comprises images having a different entity of the biological sample targeted with a predefined stain, determining spatially corresponding image pixels in the plurality of registered images, associating the spatially corresponding image pixels to a pixel profile, wherein each pixel profile comprises the pixel values of the spatially corresponding pixels and wherein the pixel profile is associated with the respective image coordinate of the spatially corresponding pixels, pooling the pixel profiles by means of a clustering method configured to determine pixel profiles with similar values, and thereby generating a plurality of clusters, each comprising pixel profiles with similar pixel values, for each cluster assigning a cluster value to the image coordinate of the pixel profiles comprised

Abstract: An occlusion device (20) includes a compliant balloon (5) including an inflation port (3) for filling and unfilling a fluid into and from a balloon chamber (26). A distal tip element (10) and a proximal base element (4) are disposed at distal and proximal sides (28B, 28A) of the balloon (5), respectively. An elongate actuating element (9) is disposed longitudinally slidable in a balloon lumen (6) forming a longitudinal passage (27) from the proximal side (28A) to the distal side (28B) of the balloon (5), connected to the distal tip element (10), and longitudinally moveable with respect to the proximal base element (4) so as to set a distance between the distal tip element (100 and the proximal base element (4). A locking mechanism (2) is configured to maintain, between the distal tip element (10) and the proximal base element (4), the distance set using the elongate actuating element (9).

Abstract: The invention relates to octadentate ligands of a general formula R1-D-X-D-X-D-X-D-E-R2, wherein D is C(O)N(OH) or N(OH)C(O), pyrimidinone or pyridinone, each X independently of any other X is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of N, C, O; R1 is alkyl, cycloalkyl, arene, or heteroarene, E is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1-50 atoms and R2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.